Marina Biotech (OTC: MRNA) discovers and develops nucleic acid-based therapeutics for rare and orphan diseases. The company’s portfolio includes single and double-stranded nucleic acid therapeutics, including siRNAs, microRNA mimics, antagomirs, and antisense compounds that are intended to trigger various RNA-based mechanisms of actions, such as RNA interference, microRNA replacement therapy, microRNA inhibition, and mRNA translational inhibition. It also focuses on patients with familial adenomatous polyposis, a rare hereditary disease; myotonic dystrophy, a disease that affects muscles and other organs in the body; and Duchenne muscular mystrophy that occurs primarily in boys, as well as to treat diseases associated with various anatomical systems. For more information, visit the company’s website at www.marinabio.com.
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
